Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …

Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

Background Among patients with resected, epidermal growth factor receptor (EGFR)–
mutated, stage IB to IIIA non–small-cell lung cancer (NSCLC), adjuvant osimertinib therapy …

Background Among patients with resectable early-stage non–small-cell lung cancer
(NSCLC), a perioperative approach that includes both neoadjuvant and adjuvant immune …

Lung cancer is the primary cause of mortality in the United States and around the globe.
Therapeutic options for lung cancer treatment include surgery, radiation therapy …

Aside from PD-L1 expression, biomarkers of response to immune checkpoint inhibitors (ICIs)
in non-small-cell lung cancer (NSCLC) are needed. In a previous retrospective analysis, we …

Tumours employ various tactics to adapt and eventually resist immune attack. These
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …

Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …

PURPOSE The open-label, phase III POSEIDON study evaluated tremelimumab plus
durvalumab and chemotherapy (T+ D+ CT) and durvalumab plus chemotherapy (D+ CT) …

Immunotherapy is used to treat almost all patients with advanced non-small cell lung cancer
(NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we …